Agilent Technologies (A) said Monday that its PD-L1 IHC 28-8 pharmDx kit was approved for two new companion diagnostic indications in the European Union.
The kit is now approved as a companion diagnostic test for malignant melanoma and non-small cell lung cancer, Agilent said.
The new approvals bring the kit's total approved indications in Europe to nine, the company said.
Price: 123.91, Change: -2.79, Percent Change: -2.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。